Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024)

Acumen Pharmaceuticals (ABOS) posted Operating Leases of $185000.0 for Q3 2024, down 15.53% sequentially from $219000.0 in Q2 2024.

Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024) Analysis & Trends

Acumen Pharmaceuticals has reported Operating Leases for 3 years, with the latest figure at $185000.0 in Q3 2024.

Quarterly Operating Leases changed N/A year-over-year to $185000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $185000.0 (changed N/A YoY) and the FY2023 annual result came in at $284000.0, changed N/A from the prior year.
Operating Leases eased to $185000.0 in Q3 2024 per ABOS's latest filing, from $219000.0 in the prior quarter.
Over five years, Operating Leases peaked at $284000.0 in Q4 2023 and troughed at $62000.0 in Q1 2022.
A 3-year average of $186000.0 and a median of $185000.0 in 2024 frame the typical range for Operating Leases.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.99 Bn	77.99 Bn	3.93 Bn
3	Argenx Se	65.00 Bn	59.82 Bn	1.37 Bn
4	Moderna	56.27 Bn	51.13 Bn	52.00 Mn
5	BeOne Medicines	42.00 Bn	36.90 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.60 Bn	28.29 Bn	992.69 Mn
7	BioNTech SE	27.68 Bn	9.29 Bn	668.28 Mn
8	Insmed	27.43 Bn	26.27 Bn	358.27 Mn
9	Royalty Pharma	27.34 Bn	26.51 Bn	-
10	Acumen Pharmaceuticals	230.12 Mn	230.12 Mn	-

Download Data